Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib
JEADV Clinical Practice · 04.07.2026
DOI: 10.1002/jvc2.70396 ↗Kurz gefasst
Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 04.07.2026. Verfasst von Melike Ak und 2 weiteren Autor:innen. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universität Zürich.
Abstract (Originalsprache)
Rosai‐Dorfman disease (RDD) is a rare histiocytic disorder with unifocal to multisystemic involvement. Activating mutations in the MAPK/ERK pathway can occur in up to 50% of RDD cases. We report a case of cutaneous RDD (C‐RDD) with facial and truncal lesions harboring an activating MAP2K1 (MEK1) mutation that showed a complete response to a combined treatment with MAPK inhibitors encorafenib and binimetinib. This case suggests that MAPK inhibitors may represent a therapeutic option for C‐RDD in certain cases.
Förderung
- Universität Zürich
Zitieren
APA
Ak, M., Dummer, R., & Ramelyte, E. (2026). Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib. JEADV Clinical Practice. https://doi.org/10.1002/jvc2.70396
Vancouver
Ak M, Dummer R, Ramelyte E. Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib. JEADV Clinical Practice. 2026. doi:10.1002/jvc2.70396
BibTeX
@article{Ak2026,
author = {Ak, Melike and Dummer, Reinhard and Ramelyte, Egle},
title = {Cutaneous Rosai‐Dorfman Disease With MAP2K1 Mutation Treated With Encorafenib and Binimetinib},
journal = {JEADV Clinical Practice},
year = {2026},
doi = {10.1002/jvc2.70396}
}
EUVIMED